Related Experiment Video
Updated: May 22, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Post-myocardial infarction hormone therapy revisited
1Department of Medicine T, Ichilov Hospital, Tel-Aviv, Israel.
Insights
Current guidelines suggest stopping hormone therapy post-heart attack, but evidence shows this may offer no benefit and could cause harm. Individual patient assessment is crucial before discontinuing therapy after myocardial infarction.
Area of Science:
- Cardiology
- Endocrinology
- Women's Health
Background:
- Current guidelines advise against postmenopausal hormone therapy (HT) for secondary prevention of coronary heart disease (CHD).
- Existing recommendations suggest discontinuing HT upon acute coronary events, including myocardial infarction (MI).
Purpose of the Study:
- To review the evidence regarding the discontinuation of hormone therapy in patients post-myocardial infarction.
- To evaluate the basis for current guidelines on stopping HT after an acute coronary event.
Main Methods:
- Literature review of studies examining hormone therapy use and cessation in post-MI patients.
- Analysis of data comparing outcomes for women who continued versus discontinued HT after MI.
Main Results:
- Evidence suggests that stopping hormone therapy post-MI offers no clear benefit.
- Cessation of HT may be associated with adverse cardiac events compared to continuation.
- The basis for current guideline recommendations is not strongly supported by available data.
Conclusions:
- Long-term hormone therapy users should not automatically discontinue treatment after myocardial infarction.
- Individualized patient evaluation is essential for making decisions about HT continuation post-MI.
- Further research may be needed to clarify optimal HT management in post-MI patients.
Abstract:
Current guidelines recommend that postmenopausal hormone therapy should not be used in the setting of secondary prevention of coronary heart disease, and that it should be stopped when an acute coronary event occurs. Reviewing the available data on the issue of discontinuation of therapy in post-myocardial infarction patients shows that the basis for this recommendation is not so solid and clear-cut. In fact, the few relevant studies concluded that cessation of hormone therapy carried no benefit, and perhaps even caused some adverse cardiac events, when compared to women who continued with treatment after they suffered a coronary event. The following article uses a recently published study as an opportunity to review this topic. Based on the literature, my personal view is that long-term hormone users should not automatically withhold therapy post-myocardial infarction, but careful individual evaluation and consideration should precede any decision.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:14Myocarditis III: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Acute Coronary Syndrome I: Introduction
01:22Myocarditis IV: Nursing Management